Associated Papers
Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells.
Gimenez-Xavier P et al.
Oncotarget, 2018
30140389 (PubMed )
Supplement: oncotarget-09-31549-s003.xlsx › Sheet1
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Rustad EH et al.
Blood Cancer Journal, 2015
25794135 (PubMed )
Supplement: bcj201524x1.xls › Sheet1
Select a paper to view details